PSNL Personalis Inc.

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Latest News

1. 07 January 2020 Personalis, Inc. Announces the Launch of the NeXT Dx™ Test, a Comprehensive Genomic Cancer Profiling Test Enabling Advanced Composite Biomarkers for Cancer Treatment

   Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, today announced the launch of the NeXT Dx™ Test to help oncologists identify potential therapies and clinical trial options for cancer patients.

2. 10 December 2019 Personalis, Inc. to Present at ESMO Immuno-Oncology Congress 2019

   Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, today announced that the company will participate in the ESMO Immuno-Oncology Congress 2019 in Geneva, Switzerland, December 11-14, including a

3. 21 November 2019 Personalis, Inc. to Present at NeoAg Summit US 2019

   Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, today announced that the company will present at the NeoAg Summit US 2019 in Boston on November 21st at 9:15 AM EST. The presentation, entitled

4. 19 November 2019 Personalis to Present at Upcoming Investor Conferences

   Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, today announced that Aaron Tachibana, Chief Financial Officer and Clinton Musil, Chief Business Officer, are scheduled to present at the

5. 19 November 2019 Personalis, Inc. Announces Collaboration With Merck KGaA, Darmstadt, Germany, to Identify and Develop Novel Biomarkers for Cancer Therapies

   Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, today announced a collaboration with Merck KGaA, Darmstadt, Germany, a leading science and technology company, to investigate novel biomarkers of

6. 17 November 2019 Personalis, Inc. to Present New Data at the AACR Tumor Immunology and Immunotherapy Conference

   Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, today announced that the company will participate in the AACR Tumor Immunology and Immunotherapy conference at the Boston Marriott Copley Place

7. 13 November 2019 Personalis Reports Third Quarter 2019 Financial Results

   Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, today reported financial results for the third quarter ended September 30, 2019. Third Quarter 2019 Highlights Record revenues of $17.2

8. 12 November 2019 Personalis, Inc. Expands Oncology Portfolio With the Launch of Cancer Whole Genome Sequencing Services

   Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, today announced the launch of Personalis' Cancer Whole Genome Sequencing which further extends Personalis' portfolio of comprehensive cancer

9. 06 November 2019 Personalis, Inc. to Present New Data at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting

   Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, today announced that the company will participate in the Society for Immunotherapy of Cancer (SITC) Annual Meeting in National Harbor, MD,